These achievements highlight the excellent therapeutic benefits achieved through reactivation of the tumor suppressor PHB2 and suggest the possibility of new therapeutics that will replace conventional endocrine therapeutics targeting E2 signaling. The gene discussed is PHB2; the disease is neoplasm.